Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023GlobeNewsWire • 08/08/23
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer ConferenceGlobeNewsWire • 08/08/23
Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceGlobeNewsWire • 08/03/23
Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals SummitGlobeNewsWire • 07/13/23
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual MeetingGlobeNewsWire • 06/29/23
ICR Hosts Plus Therapeutics CEO Marc Hedrick on the Welcome to the Arena PodcastBusiness Wire • 06/28/23
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestGlobeNewsWire • 06/14/23
Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual MeetingGlobeNewsWire • 06/08/23
Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023GlobeNewsWire • 05/30/23
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical TrialsGlobeNewsWire • 05/02/23
Plus Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 04/20/23
Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a TrialGlobeNewsWire • 04/19/23
Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual ConferenceGlobeNewsWire • 04/18/23
Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal MetastasesGlobeNewsWire • 04/18/23
Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023GlobeNewsWire • 04/12/23
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a TrialGlobeNewsWire • 03/28/23
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesGlobeNewsWire • 03/22/23
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsGlobeNewsWire • 02/23/23